Show Summary Details
Page of

Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial 

Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial
Chapter:
Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial
Author(s):

Daniel C. Brooks

DOI:
10.1093/med/9780199377527.003.0049
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 September 2019

This chapter provides a summary of a landmark study in vascular neurology. How does apixaban compare to warfarin in patients with atrial fibrillation for prevention of stroke or systemic embolism? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with atrial fibrillation and at least one other risk factor for stroke, apixaban significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and death by 11% compared to warfarin. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.